2008, Number 2
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2008; 46 (2)
Neural Defect Prevalence in 248 352 Consecutive Newborns
Hernández-Herrera RJ, Alcalá-Galván LG, Flores-Santos R
Language: Spanish
References: 13
Page: 201-204
PDF size: 95.60 Kb.
ABSTRACT
Background: neural tube defects are a scourge for the population in non developed countries.
Objective: to evaluate the prevalence of neural tube defects at a Gynecology and Obstetric Hospital at
Instituto Mexicano del Seguro Social.
Methods: it was compared two 5 years periods: one before (1995-1999 and other after (2000-2004) a State Health Department program (
Secretaría de Salud, Nuevo Léon) with 5 mg folic acid supplementation once a week to women in reproductive age.
Results: we registered 248 352 consecutive deliveries in a 10 year period, and we observed 319 cases of neural tube defects, with a global rate of 12.84 per 10 000 deliveries. From 1995 to 1999, there were 132 360, with 212 neural tube defects (16.01 rate per 10 000 deliveries); the anencephaly was 6.49, spina bifida 8.23, and encephalocele 1.28. After it was established the folic acid program, during the following period 2000 to 2004, there were 115 992 deliveries, 108 with neural tube defects (9.31 rate per 10 000 newborns), with 41.8% reduction (
p ‹ 0.001). Also decreased anencephaly rates: 28.3% (non significant) and spina bifida 63.4% (
p ‹ 0.001).
Conclusions: the neural tube defects rate has been declining in last five years comparing with 5 years before 41%, significantly more for spina bifida than anencephaly.
REFERENCES
Van der Put NM, Steegers RP, Frost P, Trijbels F, Eskes T, Van den Hervel, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1071.
Morrow JD, Kelsey K. Folic acid for prevention of neural tube defects: pediatric anticipatory guidance. J Pediatr Health Care 1998;12:55-59.
De Bree A, Van Dusseldorp M, Brower IA, Van het Hof KH, Steegers-Theunissen RP. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997;51:643-660.
Berry RJ, Zhu L, Erickson MD, Li S, Moore CA, Wong H, et al. China – US Collaborative Project for Neural Defect Prevention. Prevention of neural-tube defects with folic acid in China. N Engl J Med 1999;341:1485-1490.
Hendricks KA, Simpson JS, Larsen RD. Neural tube defects along the Texas-Mexico border 1993- 1995. Am J Epidemiol 1999; 149:1119-1127.
Rose NC, Mennutti MT. Periconceptional folic acid supplementation as a social intervention. Semin Perinatol 1995;19:243-254.
Tinkle M. Folic acid and food fortification: implications for the primary care practitioner. Nurse Pract 1997;22:105-114.
International Clearinghouse of Birth Defects Monitoring Systems, Annual Report 1999, International Center for Birth Defects, Roma, Italy.
Hernández RJ, Ortiz R. Prevalencia de malformaciones congénitas externas en Monterrey, N. L. Rev Invest Med SS 1998;3:19-21.
Martínez-de Villarreal LE, Limón-Benavides C, Valdés-Leal R, Sánchez-Peña MA, Villarreal-Pérez JZ. Efecto de la administración semanal de ácido fólico sobre los valores sanguíneos. Salud Publica Mex 2001;43:103-107.
Martínez L, Villarreal J, Arredondo P, Hernández R, Velasco M, Ambriz R, et al. Decline of neural tube defects cases after a folic acid campaign in Nuevo León, México. Teratology 2002;66:249-256.
Hernández RJ, Cerda FR, Dávila RM, Cortés GE. Estimación de la tasa de incidencia de algunos defectos congénitos en Monterrey, México. Ginecol Obstet Mex 2002;70:597-600.
Wald NJ. Folic acid and the prevention of neural tube defects. N Engl J Med 2004;350:101-103.
Full text